News headlines about Imprimis Pharmaceuticals (NASDAQ:IMMY) have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Imprimis Pharmaceuticals earned a daily sentiment score of 0.00 on Accern’s scale. Accern also gave media coverage about the specialty pharmaceutical company an impact score of 45.5230185795583 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Separately, Zacks Investment Research upgraded shares of Imprimis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th.

Shares of Imprimis Pharmaceuticals (IMMY) traded down 3.01% during mid-day trading on Friday, hitting $1.61. The stock had a trading volume of 61,257 shares. Imprimis Pharmaceuticals has a 1-year low of $1.47 and a 1-year high of $4.69. The stock’s 50-day moving average is $1.99 and its 200 day moving average is $3.03. The firm’s market capitalization is $32.30 million.

Imprimis Pharmaceuticals (NASDAQ:IMMY) last released its quarterly earnings results on Thursday, August 10th. The specialty pharmaceutical company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.29. The business had revenue of $6.86 million for the quarter. Imprimis Pharmaceuticals had a negative net margin of 57.07% and a negative return on equity of 242.66%. Equities research analysts predict that Imprimis Pharmaceuticals will post ($0.86) EPS for the current fiscal year.

In other news, Director Robert J. Kammer sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $3.05, for a total value of $30,500.00. Following the completion of the sale, the director now directly owns 1,059,827 shares of the company’s stock, valued at approximately $3,232,472.35. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 12.55% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This report was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at

About Imprimis Pharmaceuticals

Imprimis Pharmaceuticals, Inc (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment.

Insider Buying and Selling by Quarter for Imprimis Pharmaceuticals (NASDAQ:IMMY)

Receive News & Ratings for Imprimis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.